Aducanumab

Specification

• Cat#: THA-0088
• Product Name: Aducanumab
• Description: Aducanumab is a monoclonal antibody indicated in the treatment of Alzheimer's disease.
• Sequences: Not Available
• Molecular Weight: 146000.0 Da (Approximate)
• Introduction: Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to gantenerumab, bapineuzumab and solanezumab. Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and phase 1b clinical trial data have shown patients treated with aducanumab show a reduction in amyloid-β plaques. Based on Mini-Mental State Examination and Clinical Dementia Rating (CDR), patients taking aducanumab showed signs of slowing progression; however, these data were controversial. Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18. Although aducanumab's approval represents the first drug treatment for Alzheimer's disease, the approval is conditional on further results. Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard deviation. Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing the data and aducanumab was granted accelerated FDA approval on 7 June 2021. In January 2024, Biogen announced that the development and commercialization of aducanumab will be discontinued to prioritize the marketing of lecanemab, another drug approved for the treatment of Alzheimer's disease.
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: Not Available
• Appearance: Liquid

Pharmaceutical Information

• Pharmacodynamics: Aducanumab is a monoclonal IgG1 antibody that binds to amyloid-β, reducing amyloid plaques in the brain. It has a long duration of action as it is given once every 4 weeks. Patients should be counselled regarding the risk of amyloid related imaging abnormalities, including microhemorrhages, and hypersensitivity reactions.
• Targets: Amyloid-beta precursor protein